Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: A clinical perspective and emerging treatment options

Elias J. Jabbour, Jorge E. Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to respond, respond suboptimally, or experience disease relapse after treatment with imatinib. A key factor is drug resistance. The molecular mechanisms implicated in this resistance include those that involve upregulation or mutation of BCR-ABL kinase and those that are BCR-ABL independent. The clinical consequences of these molecular mechanisms of resistance for disease pathogenesis remain open for debate. This review summarizes the molecular mechanisms and clinical consequences of TKI resistance and addresses the current and future treatment approaches for patients with TKI-resistant CML.

Original languageEnglish (US)
Pages (from-to)515-529
Number of pages15
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number5
DOIs
StatePublished - Oct 1 2013
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Disease Resistance
Drug Resistance
Phosphotransferases
Up-Regulation
Therapeutics
Recurrence
Mutation

Keywords

  • BCR-ABL mutations
  • Molecular mechanisms
  • T315I

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia : A clinical perspective and emerging treatment options. / Jabbour, Elias J.; Cortes, Jorge E.; Kantarjian, Hagop M.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 5, 01.10.2013, p. 515-529.

Research output: Contribution to journalReview article

@article{3949fba5766d439e93d7810c03d86a90,
title = "Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: A clinical perspective and emerging treatment options",
abstract = "The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many patients with chronic myelogenous leukemia (CML). However, 20{\%} to 30{\%} of patients fail to respond, respond suboptimally, or experience disease relapse after treatment with imatinib. A key factor is drug resistance. The molecular mechanisms implicated in this resistance include those that involve upregulation or mutation of BCR-ABL kinase and those that are BCR-ABL independent. The clinical consequences of these molecular mechanisms of resistance for disease pathogenesis remain open for debate. This review summarizes the molecular mechanisms and clinical consequences of TKI resistance and addresses the current and future treatment approaches for patients with TKI-resistant CML.",
keywords = "BCR-ABL mutations, Molecular mechanisms, T315I",
author = "Jabbour, {Elias J.} and Cortes, {Jorge E.} and Kantarjian, {Hagop M.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.clml.2013.03.018",
language = "English (US)",
volume = "13",
pages = "515--529",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "5",

}

TY - JOUR

T1 - Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia

T2 - A clinical perspective and emerging treatment options

AU - Jabbour, Elias J.

AU - Cortes, Jorge E.

AU - Kantarjian, Hagop M.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to respond, respond suboptimally, or experience disease relapse after treatment with imatinib. A key factor is drug resistance. The molecular mechanisms implicated in this resistance include those that involve upregulation or mutation of BCR-ABL kinase and those that are BCR-ABL independent. The clinical consequences of these molecular mechanisms of resistance for disease pathogenesis remain open for debate. This review summarizes the molecular mechanisms and clinical consequences of TKI resistance and addresses the current and future treatment approaches for patients with TKI-resistant CML.

AB - The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to respond, respond suboptimally, or experience disease relapse after treatment with imatinib. A key factor is drug resistance. The molecular mechanisms implicated in this resistance include those that involve upregulation or mutation of BCR-ABL kinase and those that are BCR-ABL independent. The clinical consequences of these molecular mechanisms of resistance for disease pathogenesis remain open for debate. This review summarizes the molecular mechanisms and clinical consequences of TKI resistance and addresses the current and future treatment approaches for patients with TKI-resistant CML.

KW - BCR-ABL mutations

KW - Molecular mechanisms

KW - T315I

UR - http://www.scopus.com/inward/record.url?scp=84884137284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884137284&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.03.018

DO - 10.1016/j.clml.2013.03.018

M3 - Review article

C2 - 23890944

AN - SCOPUS:84884137284

VL - 13

SP - 515

EP - 529

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 5

ER -